Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
8 stopped studies mapped to Renal Pelvis and Ureter Carcinoma and descendants · 100% state a reason
Over the 8 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT05564416 | Testing Anti-Cancer Drugs Erdafitinib With or Without Atezolizumab in Patients With… | Phase 2 | withdrawn | Oct 3, 2022 | National Cancer Institute (NCI) | Feasibility issues | Other (stated, no rule matched) |
| NCT04228042 | Infigratinib Before Surgery for the Treatment of Upper Tract Urothelial Cancer | Phase 1 / Phase 2 | terminated | Jan 14, 2020 | M.D. Anderson Cancer Center | Drug manufacturer made the business decision to cease all infigratinib oncology research in the US… | Drug supply |
| NCT04871529 | Testing the Addition of an Anti-Cancer Immunotherapy Drug, Avelumab, to Gemcitabine and… | Phase 2 | terminated | May 4, 2021 | SWOG Cancer Research Network | inability to accrue sufficient patients | Enrollment / accrual |
| NCT04197986 | Oral Infigratinib for the Adjuvant Treatment of Subjects With Invasive Urothelial…(PROOF302) | Phase 3 | terminated | Dec 13, 2019 | QED Therapeutics, a BridgeBio company | The sponsor has decided to close the study due to the discontinuation of infigratinib development.… | Safety / toxicity |
| NCT03606174 | A Phase 2 Study of Sitravatinib in Combination With PD-(L)1 Checkpoint Inhibitor Regimens… | Phase 2 | terminated | Jul 30, 2018 | Mirati Therapeutics Inc. | The study was terminated due to sponsor decision / portfolio prioritization, and not due to safety… | Safety / toxicity |
| NCT04398368 | Gemcitabine for the Prevention of Intravesical Recurrence of Urothelial Cancer in… | Phase 2 | terminated | May 21, 2020 | Mayo Clinic | Focus research efforts on other projects. | Other (stated, no rule matched) |
| NCT03397394 | Rucaparib in Patients With Locally Advanced or Metastatic Urothelial Carcinoma(ATLAS) | Phase 2 | terminated | Jan 12, 2018 | pharmaand GmbH | Efficacy did not meet the continuance criteria and DMC recommended to stop enrollment. | Efficacy / futility |
| NCT03935347 | Adoptive Cell Therapy With (LN-145) in Combination With Pembrolizumab in Treating… | Phase 2 | withdrawn | May 2, 2019 | Roswell Park Cancer Institute | no accrual | Enrollment / accrual |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 22 days agoSource updated Oct 21, 2025source: clinicaltrials